Pharmacodynamics of fosfomycin: Insights into clinical use for antimicrobial resistance

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 9, 2015, Pages 5602-5610

  Docobo Perez F ^a   Drusano, G L ^b   Johnson, A ^c   Goodwin, J ^c   Whalley, S ^c   Ramos Martin V ^c   Ballestero Tellez, M ^a   Rodriguez Martinez, J M ^d   Conejo, M C ^d   Van Guilder, M ^e   Rodriguez Bano J ^a,d   Pascual, A ^a,d   Hope, W W ^c  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d UNIVERSITY OF SEVILLE   (Spain)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOSFOMYCIN SODIUM; MEROPENEM; ANTIINFECTIVE AGENT; FOSFOMYCIN; THIENAMYCIN DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GROWTH; BACTERIAL LOAD; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; COLONY FORMING UNIT; CONTROLLED STUDY; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; HOLLOW FIBER; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MUTATION RATE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; STEADY STATE; URINARY TRACT INFECTION; DRUG EFFECTS; ESCHERICHIA COLI; GENETICS; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; MUTATION;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; FOSFOMYCIN; MICROBIAL SENSITIVITY TESTS; MUTATION; THIENAMYCINS;

EID: 84940933804     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00752-15     Document Type: Article

References (30)

1. Rodriguez-Ba?o J, Picon E, Gijon P, Hernandez JR, Ruiz M, Pena C, Almela M, Almirante B, Grill F, Colomina J, Gimenez M, Oliver A, Horcajada JP, Navarro G, Coloma A, Pascual A, Spanish Network for Research in Infectious Diseases (REIPI). 2010. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis 50:40-48. http://dx.doi.org /10.1086/649537.
2. Rodriguez-Ba?o J, Navarro MD, Romero L, Muniain MA, de Cueto M, Rios MJ, Hernandez JR, Pascual A. 2006. Bacteremia due to extendedspectrum beta-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 43:1407-1414. http://dx.doi.org/10 .1086/508877.
3. Rodriguez-Bano J, Lopez-Prieto MD, Portillo MM, Retamar P, Natera C, Nuno E, Herrero M, del Arco A, Munoz A, Tellez F, Torres-Tortosa M, Martin-Aspas A, Arroyo A, Ruiz A, Moya R, Corzo JE, Leon L, Perez-Lopez JA, SAEI/SAMPAC Bacteraemia Group. 2010. Epidemiology and clinical features of community-acquired, healthcare-associated and nosocomial bloodstream infections in tertiary-care and community hospitals. Clin Microb Infect 16:1408-1413. http://dx.doi.org/10.1111/j .1469-0691.2010.03089.x.
4. Pitout JD, Laupland KB. 2008. Extended-spectrum beta-lactamaseproducing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 8:159-166. http://dx.doi.org/10.1016/S1473-3099(08)70041-0.
5. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. 2012. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 25: 682-707. http://dx.doi.org/10.1128/CMR.05035-11.
6. Rosso-Fernandez C, Sojo-Dorado J, Barriga A, Lavin-Alconero L, Palacios Z, Lopez-Hernandez I, Merino V, Camean M, Pascual A, Rodriguez-Bano JFOREST Study Group. 2015. Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum beta-lactamaseproducing Escherichia coli (FOREST): study protocol for an investigatordriven randomised controlled trial. BMJ Open 5:e007363. http://dx.doi .org/10.1136/bmjopen-2014-007363.
7. Skarzynski T, Mistry A, Wonacott A, Hutchinson SE, Kelly VA, Duncan K. 1996. Structure of UDP-N-acetylglucosamine enolpyruvyl transferase, an enzyme essential for the synthesis of bacterial peptidoglycan, complexed with substrate UDP-N-acetylglucosamine and the drug fosfomycin. Structure 4:1465-1474. http://dx.doi.org/10 .1016/S0969-2126(96)00153-0.
8. de Cueto M, Lopez L, Hernandez JR, Morillo C, Pascual A. 2006. In vitro activity of fosfomycin against extended-spectrum beta-lactamaseproducing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures. Antimicrob Agents Chemother 50:368-370. http://dx.doi.org/10.1128/AAC.50.1.368-370.2006.
9. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing, 23rd informational supplement. CLSI document M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.
10. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE, Infectious Diseases Society of America, European Society for Microbiology and Infectious Diseases. 2011. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52:e103-e120. http://dx.doi.org/10.1093/cid/ciq257.
11. Karageorgopoulos DE, Wang R, Yu XH, Falagas ME. 2012. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antimicrob Chemother 67:255-268. http://dx.doi.org/10.1093/jac/dkr466.
12. Felton TW, Goodwin J, O'Connor L, Sharp A, Gregson L, Livermore J, Howard SJ, Neely MN, Hope WW. 2013. Impact of bolus dosing versus continuous infusion of piperacillin and tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 57:5811-5819. http://dx.doi.org/10.1128 /AAC.00867-13.
13. Pfausler B, Spiss H, Dittrich P, Zeitlinger M, Schmutzhard E, Joukhadar C. 2004. Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculi- tis. J Antimicrob Chemother 53:848-852. http://dx.doi.org/10.1093/jac /dkh158.
14. Mouton JW, Touzw DJ, Horrevorts AM, Vinks AA. 2000. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokin 39:185-201. http://dx.doi.org/10.2165/00003088-200039030 -00002.
15. Li L, Chen X, Dai X, Chen H, Zhong D. 2007. Rapid and selective liquid chromatographic/tandem mass spectrometric method for the determination of fosfomycin in human plasma. J Chromatogr B 856:171-177. http: //dx.doi.org/10.1016/j.jchromb.2007.05.037.
16. Gonzalez D, Schmidt S, Derendorf H. 2013. Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents. Clin Microbiol Rev 26:274-288. http://dx.doi.org/10.1128/CMR .00092-12.
17. Neely MN, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW. 2012. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monitor 34:467-476. http://dx.doi.org/10 .1097/FTD.0b013e31825c4ba6.
18. Drusano GL, Neely M, Van Guilder M, Schumitzky A, Brown D, Fikes S, Peloquin C, Louie A. 2014. Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis. PLoS One 9:e101311. http://dx.doi.org/10.1371/journal.pone.0101311.
19. Leary RH, Jelliffe R, Schumitzky A, Van Guilder M. 2001. An adaptive grid non-parametric approach to population pharmacokinetic/dynamic (PK/PD) population models, p 389-394. In Proceedings 14th IEEE Symposium on Computer-Based Medical Systems. IEEE, New York, NY.
20. Hendlin D, Stapley EO, Jackson M, Wallick H, Miller AK, Wolf FJ, Miller TW, Chaiet L, Kahan FM, Foltz EL, Woodruff HB, Mata JM, Hernandez S, Mochales S. 1969. Phosphonomycin, a new antibiotic produced by strains of streptomyces. Science 166:122-123. http://dx.doi .org/10.1126/science.166.3901.122.
21. Roussos N, Karageorgopoulos DE, Samonis G, Falagas ME. 2009. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int J Antimicrob Agents 34:506-515. http://dx.doi.org/10.1016/j .ijantimicag.2009.08.013.
22. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. 2010. Fosfomycin for the treatment of multidrug-resistant, including extendedspectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 10:43-50. http://dx.doi.org/10.1016 /S1473-3099(09)70325-1.
23. Pulcini C, Bush K, Craig WA, Frimodt-Moller N, Grayson ML, Mouton JW, Turnidge J, Harbarth S, Gyssens IC, ESCMID Study Group for Antibiotic Policies. 2012. Forgotten antibiotics: an inventory in Europe, the United States, Canada, and Australia. Clin Infect Dis 54:268-274. http: //dx.doi.org/10.1093/cid/cir838.
24. Agencia Espa?ola de Medicamentos y Productos Sanitarios. 2013. Fosfomicina. Spanish Agency of Medicines and Medical Devices, Madrid, Spain. http://www.aemps.gob.es/cima/pdfs/es/ft/54165/FT-54165.pdf.
25. Medicines and Healthcare Products Regulatory Agency. 2015. Fosfomycin sodium. MHRA, London, England. http://www.mhra.gov.uk /home/groups/par/documents/websiteresources/con309596.pdf.
26. Kahan FM, Kahan JS, Cassidy PJ, Kropp H. 1974. The mechanism of action of fosfomycin (phosphonomycin). AnnNY Acad Sci 235:364-386. http://dx.doi.org/10.1111/j.1749-6632.1974.tb43277.x.
27. Grimm H. 1979. In vitro investigations with fosfomycin on Mueller- Hinton agar with and without glucose-6-phosphate. Infection 7:256-259. http://dx.doi.org/10.1007/BF01648937.
28. European Committee on Antimicrobial Susceptibility Testing. 2015. Breakpoint tables for interpretation of MICs and zone diameters, version 5.0. EUCAST, V?xj?, Sweden. http://www.eucast.org/. Accessed 30 April 2015.
29. Sauermann R, Karch R, Langenberger H, Kettenbach J, Mayer-Helm B, Petsch M, Wagner C, Sautner T, Gattringer R, Karanikas G, Joukhadar C. 2005. Antibiotic abscess penetration: fosfomycin levels measured in pus and simulated concentration-time profiles. Antimicrob Agents Chemother 49:4448-4454. http://dx.doi.org/10.1128/AAC.49.11.4448-4454 .2005.
30. Tangden T, Adler M, Cars O, Sandegren L, Lowdin E. 2013. Frequent emergence of porin-deficient subpopulations with reduced carbapenem susceptibility in ESBL-producing Escherichia coli during exposure to ertapenem in an in vitro pharmacokinetic model. J Antimicrob Chemother 68:1319-1326. http://dx.doi.org/10.1093/jac/dkt044.